Xwell, INC 8-K filings

XWELL, Inc. has implemented a Tax Benefits Preservation Plan to safeguard approximately $67.3 million in potential tax reductions.

XWELL, Inc. announced a 14% revenue increase in Q2 2024 compared to the same period last year, alongside significant cost reductions and strategic expansions.

XWELL, Inc. has entered into agreements for a registered direct offering of 652,705 shares at $2.18 per share, expected to close around August 8, 2024, raising approximately $1.4 million.

XWELL Inc. has declared the director nominations submitted by CPC Pain & Wellness invalid due to deficiencies in their filing and is urging shareholders to be cautious of communications from CPC.

XWELL, Inc. has updated its bylaws to include a more structured process for stockholders to propose business or nominate directors at annual meetings.

XWELL, Inc. announced a 24% year-over-year revenue increase and a 62% reduction in operating losses for the first quarter of 2024, demonstrating significant progress towards profitability.

XWELL, Inc. announced its 2023 financial results, showcasing revenue growth in its XpresSpa segment and significant cost reductions, while also expanding its biosurveillance program and out-of-airport presence.

XWELL Inc. will restate its Q3 2023 financial statements due to an accounting error related to the impairment of its Treat business segment, leading to a material weakness in internal controls.

XWELL, Inc. has announced it will file a notification of late filing for its annual report, seeking a 15-day extension.

XWELL, in collaboration with Ginkgo Bioworks and the CDC, is expanding its traveler-based genomic surveillance program to Miami and Chicago airports, with an estimated $36.7 million extension.

XWELL Inc. has appointed Galle S. Wizenberg to both the Audit and Compensation Committees, effective January 30, 2024.